BPC 157 Side Effects: What the Animal and Human Evidence Shows

BPC 157 side effects: why there is no reliable list

A side-effect profile normally comes from phase 1 to phase 3 trials: hundreds or thousands of people, a placebo group, and adverse events recorded at every visit. BPC-157 has never been through that process. It is not on the Australian Register of Therapeutic Goods (ARTG), no regulator anywhere has approved it, and the 2025 systematic review by Vasireddi and colleagues in HSS Journal, which searched PubMed, Cochrane and Embase up to June 2024, found no clinical safety data to summarise.

So any article that gives you a neat bullet list of BPC-157 side effects with percentages is inventing it. What does exist falls into four buckets: rat and mouse studies, a handful of small human reports, theoretical concerns drawn from the mechanism, and the very practical risk of an impure or mislabelled product. We take them in that order.

What animal studies report

BPC-157 is a 15 amino acid fragment (GEPPPGKPADDAGLV) of a protein found in human gastric juice, and most of its record comes from Professor Predrag Sikiric's group at the University of Zagreb. Across three decades of rat work (tendon, ligament, muscle, gut, liver and blood vessel models) the Zagreb papers consistently describe it as free of toxic effects in the animals studied. Independent groups, such as the Taiwanese team behind Chang et al. 2011 in the Journal of Applied Physiology, did not report toxicity in their tendon models either.

Two cautions apply. First, most of this literature comes from one laboratory, and replication by unrelated groups is thin. Second, a rat model looks for the outcome it was designed to measure, usually healing, not for rare or slow-developing harms. "No adverse effects observed" in a two-week tendon study is not the same thing as a safety profile.

The few human reports on side effects of BPC 157

Only three human reports have been published, and all three come from the same Florida clinician, Dr Edwin Lee. The 2025 narrative review in Current Reviews in Musculoskeletal Medicine lists them:

• Knee pain chart review (Lee and Padgett, Alternative Therapies in Health and Medicine, 2021). A retrospective look at 16 patients given intra-articular BPC-157, some with thymosin beta-4. Fourteen reported pain relief and no serious adverse events were recorded. There was no control group and no standardised outcome measure.
• Interstitial cystitis series (Lee and colleagues, 2024). Twelve patients received bladder instillations; the authors reported improvement in all 12.
• Intravenous safety pilot (Lee and Burgess, Alternative Therapies in Health and Medicine, 2025). Two healthy adults, a 58-year-old man and a 68-year-old woman, received 10 mg then 20 mg by infusion on consecutive days. Cardiac, liver, kidney, thyroid and glucose markers did not change, and plasma levels returned to baseline within 24 hours.

Before that, an enema formulation coded PL 14736 went into phase II trials for ulcerative colitis through the Croatian company Pliva, and the Zagreb group describes it as well tolerated there. Full independent trial reports are hard to find.

Put together, that is roughly 30 people, no randomised placebo-controlled trial and follow-up measured in days to months. It rules out nothing rare. The Australian men's health body Healthy Male makes the same point: the biggest drawback is that there is not enough evidence of safety.

BPC 157 side effects in men and women

Searches for BPC 157 side effects in men usually ask about hormones: testosterone, fertility, libido. No published study has measured any of these in people, and there is no sex-specific adverse event data for men or women. The intravenous pilot included one man and one woman, which cannot show a difference either way. Anyone claiming BPC-157 affects, or does not affect, male hormones is going beyond the evidence.

The theoretical concern: angiogenesis and cancer

The most discussed question is not an observed side effect but a mechanism. BPC-157 is pro-angiogenic in animal models, meaning it encourages new blood vessel growth. Hsieh and colleagues (Journal of Molecular Medicine, 2017) showed it up-regulates VEGFR2, the main receptor for vascular endothelial growth factor, and activates the downstream Akt-eNOS pathway in endothelial cells. That is useful in a healing tendon. It is also the same receptor tumours rely on to build a blood supply once they grow beyond a millimetre or two.

No study has shown BPC-157 causes or accelerates cancer. A 2004 report in Melanoma Research described the opposite in one human melanoma cell line, with reduced growth and VEGF signalling. But no long-term carcinogenicity study exists either, and the 2025 review in Current Reviews in Musculoskeletal Medicine lists pathological angiogenesis and tumour promotion as open theoretical risks, alongside nitric oxide effects. Our view: treat the cancer question as unanswered, not answered in either direction, and design research accordingly.

The practical risk: what is actually in the vial

For most people asking whether BPC-157 is safe, the bigger real-world risk is the product, not the peptide. In April 2026 the TGA warned that unapproved peptide products, BPC-157 among them, are often supplied in poorly labelled or unmarked vials, with risks of contamination, wrong content and non-sterile manufacture, and it has received adverse event reports for such products that include severe allergic reactions. A 15-residue peptide with three prolines in a row is not hard to make badly: truncated sequences, leftover synthesis reagents and underfilled vials all show up in unverified material.

That is why a certificate of analysis matters more for this compound than most. A useful COA names the lot, confirms identity by mass spectrometry (BPC-157 has a molecular weight of about 1419 Da) and reports purity by HPLC. Every AminoBlend lot is tested by an independent laboratory for both, and the lot number on each vial matches its certificate on our lot-matched COA lookup. Our guide on reading a peptide certificate of analysis shows what to check, and our testing process explains how lots are released.

Sport: BPC-157 is prohibited at all times

BPC-157 has been on the World Anti-Doping Agency Prohibited List since 2022 under S0, Non-Approved Substances, which covers any substance with no current approval by a government health authority for human therapeutic use. S0 substances are banned in and out of competition. Sport Integrity Australia publishes a BPC-157 page carrying the same status. The related peptide TB-500 is prohibited under S2; see our TB-500 explainer for that side of the picture.

Research use and further reading

For background on the compound itself, read what BPC-157 is and where it came from, and for the regulatory position see BPC-157 and Australian law. The BPC-157 reconstitution calculator works out solution concentration for the 10 mg vial, and the wider tissue repair peptide range sits in one place.

Where to Buy BPC-157 With a Lot-Matched Certificate

The practical risk covered above is the one a buyer can control. Before you buy BPC-157 for laboratory research, match the lot number printed on the vial to its report in our COA library, where an outside laboratory reports the mass spectrometry identity check and HPLC purity figure for each lot. AminoBlend sells BPC-157 as a 10 mg vial for $69 or 60 capsules for $79 online from Australian stock, so there is no stockist to track down. Projects that pair it with thymosin beta-4 can buy the TB-500 10 mg vial or the premixed Wolverine blend at the same time, and a vial of bacteriostatic water covers reconstitution. Shop the range online and buy only what the protocol needs.

AminoBlend supplies BPC-157 for laboratory research only. It is not for use in people or animals, and this page gives no medical or dosing advice.